DSGN Stock Price Quote
Table Of Content Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results Design Therapeutics (DSGN) Earnings Date, Estimates & Call Transcripts Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results This makes it difficult to properly value the company and its stock, as Design Therapeutics has no price-to-earnings (P/E) ratio since it has no earnings. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stage trial of a treatment for Friedreich ataxia, a ge... Yes, I think it's an issue for all doses. Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track Design’s lead program is focused on...